## **CENTER FOR DRUG EVALUATION AND** RESEARCH

**APPLICATION NUMBER: 20-965** 

## **ADMINISTRATIVE DOCUMENTS**



1 of

### FDA CDER EES ESTABLISHMENT EVALUATION REQUEST SUMMARY REPORT

Application:	NDA	20965/00
--------------	-----	----------

Priority: 1S

Org Code: 540

Stamp: 01-JUL-1998 Regulatory Due: 04-DEC-1999

Action Goal:

District Goal: 02-MAR-1999

Applicant:

**DUSA** 

Brand Name:

**LEVULAN** 

KERASTICK(AMINOLEVULINIC

**ACID HC** 

Established Name:

Generic Name: AMINOLEVULINIC ACID HCL

Dosage Form: SOL (SOLUTION)

Strength:

20%

FDA Contacts:

O. CINTRON

**400 COLUMBUS AVE** 

VALHALLA, NY 10595

(HFD-540)

301-827-2023 , Project Manager

J. HATHAWAY

(HFD-540)

301-827-2069 , Review Chemist

W. DECAMP II

(HFD-540)

301-827-2041 , Team Leader

### Overall Recommendation:

ACCEPTABLE on 12-NOV-1999 by M. EGAS (HFD-322) 301-594-0095 WITHHOLD on 07-APR-1999 by J. D AMBROGIO (HFD-324) 301-827-0062

Establishment: 1052961

DMF No:

**GUIDELINES ANALYTICAL LABORA** AADA No:

10320 USA TODAY WAY MIRIMAR, FL 33025

Profile: CTL

OAI Status: NONE

Responsibilities: FINISHED DOSAGE STABILITY

**TESTER** 

Last Milestone: OC RECOMMENDATION

Milestone Date: 28-JUL-1998 Decision:

**ACCEPTABLE** 

Reason:

**BASED ON PROFILE** 

Establishment: 1217998

NORTH SAFETY PRODUCTS

2000 PLAINFIELD PIKE CRANSTON, RI 02920

Profile: LIQ

OAI Status: NONE

DMF No:

AADA No:

Responsibilities: FINISHED DOSAGE

**MANUFACTURER** 

Last Milestone: OC RECOMMENDATION

Milestone Date: 07-APR-1999

Decision:

**ACCEPTABLE** 

Reason:

DISTRICT RECOMMENDATION

Establishment

DMF No: AADA No:

Profile: CSN

OAI Status: NONE



02-DEC-1999

### FDA CDER EES ESTABLISHMENT EVALUATION REQUEST **SUMMARY REPORT**

2 of Page

Responsibilities: DRUG SUBSTANCE MANUFACTURER

Last Milestone: OC RECOMMENDATION

Decision:

Milestone Date: 04-NOV-1999 **ACCEPTABLE** 

Reason:

DISTRICT RECOMMENDATION

APPEARS THIS WAY ON ORIGINAL



## DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION

Form Approved: OMB No. 0910-0217 Expiration Date: 04-30-01

## **USER FEE COVER SHEET**

	verse Side Before Completing This Form	
DUSA Pharmaceuticals.Inc.	J. PRODUCTNAME  LEVULAN (aminolevulinic acid HCI) Kerastick (Aminolevulinic acid HCI)	
400 Columbus Avenue	for Topical Solution, 20% 4. DOES THIS APPLICATION REQUIRE CLINICAL DATA FOR APPROVAL?	
Valhalla, NY 10595	IF YOUR RESPONSE IS "NO" AND THIS IS FOR A SUPPLEMENT, STOP HERE AND SIGN THIS FORM.	
	IF RESPONSE IS 'YES', CHECK THE APPROPRIATE RESPONSE BELOW:	
	THE REQUIRED CLINICAL DATA ARE CONTAINED IN THE APPLICATION.	
	THE REQUIRED CLINICAL DATA ARE SUBMITTED BY REFERENCE TO	
2. TELEPHONE NUMBER (Include Area Code)	(APPLICATION NO. CONTAINING THE DATA).	
( 914 ) 747–4300		
5. USER FEE I.D. NUMBER	6. LICENSE NUMBER / NOA NUMBER	
<b>3494</b>	20-965	
7. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USE		
A LARGE VOLUME PARENTERAL DRUG PRODUCT APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT BEFORE 9/1/92 (Self Explanatory)	A 505(b)(2) APPLICATION THAT DOES NOT REQUIRE A FEE (See item 7, reverse side before checking box.)	
THE APPLICATION QUALIFIES FOR THE ORPHAN EXCEPTION UNDER SECTION 736(a)(1)(E) of the Federal Drug, and Cosmetic Act (See item 7, reverse side before checking box.)	Food,  THE APPLICATION IS A PEDIATRIC SUPPLEMENT THAT  QUALIFIES FOR THE EXCEPTION UNDER SECTION 736(a)(1)(F) of the Federal Food, Drug, and Cosmetic Act (See item 7, reverse side before checking box.)	
THE APPLICATION IS GOVERNMENT ENTI COMMERCIALLY (Self Explanatory)	IS SUBMITTED BY A STATE OR FEDERAL TTY FOR A DRUG THAT IS NOT DISTRIBUTED	
FOR BIO	DLOGICAL PRODUCTS ONLY	
WHOLE BLOOD OR BLOOD COMPONENT FOR TRANSFUSION	WHOLE BLOOD OR BLOOD COMPONENT FOR A CRUDE ALLERGENIC EXTRACT PRODUCT TRANSFUSION	
AN APPLICATION FOR A BIOLOGICAL PRODUCT FOR FURTHER MANUFACTURING USE ONLY	AN "IN VITRO" DIAGNOSTIC BIOLOGICAL PRODUCT LICENSED UNDER SECTION 351 OF THE PHS ACT	
BOVINE BLOOD PRODUCT FOR TOPICAL APPLICATION LICENSED BEFORE 9/1/92		
B. HAS A WAIVER OF AN APPLICATION FEE BEEN GRANTED FOR THIS	S APPLICATION? YES Y NO (See reverse side if answered YES)	
A completed form must be signed and accompany each new drug or biologic product application and each new supplement. If payment is sent by U.S. mail or courier, please include a copy of this completed form with payment.		
iristructions, searching existing data sources, dathering and mail	is estimated to average 30 minutes per response, including the time for reviewing intaining the data needed, and completing and reviewing the collection of information, to fithis collection of information, including suggestions for reducing this burden to:	
DHHS, Reports Clearance Officer  Paperwork Reduction Project (0910-0297)  Hubert H. Humphrey Building, Room 531-H 200 Independence Avenue, S.W.  Washington, DC 20201  An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.		
Please DO NOT RETURN this form to this address.		
GNATURE OF AUTHORIZED COMPANY REPRESENTATIVE	TITLE DATE	
( / <b>S</b> / - )	Vice President, Scientific Affairs 06/16/98	



## DUSλ

DUSA PHARMACEUTICALS, INC 400 COLUMBUS ALENUE VALHALLA NY 10595

TEL 914.747.4300

FAX 914.747.7563

### **DEBARMENT CERTIFICATION**

DUSA Pharmaceuticals, Inc., hereby certifies that pursuant to Section 306 (k) (1) of the act (21 U.S.C. 335a (k) (1), we did not and will not use in any capacity the services of any person debarred under Subsections (a) or (b) [Section 306 (a) or (b)], of the Federal Food, Drug, and Cosmetic (FDC) Act in connection with this application.

Stuart L. Marcus, MD, PhD

Senior Vice President, Scientific Affairs

And Chief Scientific Officer

DUSA Pharmaceuticals, Inc.

APPEARS THIS WAY ON ORIGINAL



# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

